ChromoGenics AB reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 2.84 million compared to SEK 6.4 million a year ago. Revenue was SEK 3.42 million compared to SEK 6.75 million a year ago.

Net loss was SEK 13.61 million compared to SEK 13.09 million a year ago. Basic loss per share from continuing operations was SEK 3.3 compared to SEK 9.2 a year ago. Diluted loss per share from continuing operations was SEK 3.3 compared to SEK 9.2 a year ago.